

Takeshi Kumada

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8239797/takeshi-kumada-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131
papers

4,197
citations

32
h-index

63
g-index

157
ext. papers

5,710
ext. citations

5.3
avg, IF

5.08
L-index

#	Paper	IF	Citations
131	Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection.. <i>European Radiology</i> , 2022 , 1	8	
130	Liver biopsy implementation rate for diagnosis of NASH in Japan -analysis of big data of health insurance claims-. <i>Acta Hepatologica Japonica</i> , 2022 , 63, 211-213	0.3	
129	Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups.. <i>BMC Gastroenterology</i> , 2022 , 22, 241	3	0
128	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.. <i>Scientific Reports</i> , 2022 , 12, 8421	4.9	0
127	Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era. <i>Oncology</i> , 2021 , 1-9	3.6	
126	Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population. <i>Hepatology Research</i> , 2021 , 52, 81	5.1	3
125	Utility of Ultrasound-Guided Attenuation Parameter for Grading Steatosis With Reference to MRI-PDFF in a Large Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
124	Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, e898-e904	2.2	0
123	Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 32, 255-260	2.2	5
122	Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 32, 261-268	2.2	5
121	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 1812-1819	4	10
120	Abnormal fucosylation of alpha-fetoprotein in patients with nonalcoholic steatohepatitis. <i>Hepatology Research</i> , 2021 , 51, 548-553	5.1	1
119	A New Ultrasonographic "Fluttering Sign" for Hepatic Hemangioma. <i>Ultrasound in Medicine and Biology</i> , 2021 , 47, 941-946	3.5	1
118	Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 1309-1316	6.1	1
117	Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 1001-1013	6.2	0
116	Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 ,	2.2	1
115	Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00337	4.2	1

114	Characteristics and Prognosis of Hepatocellular Carcinoma After Sustained Virologic Response. <i>Hepatology Communications</i> , 2021 , 5, 1290-1299	6	1
113	Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. <i>Hepatology Research</i> , 2021 , 51, 880-889	5.1	4
112	Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. <i>Hepatology Research</i> , 2021 , 51, 860-869	5.1	3
111	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. <i>Cancer Reports</i> , 2021 , e1464	1.5	7
110	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2021 ,	7.9	3
109	Serum Levels of α Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 162-170.e4	6.9	10
108	Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 168-176	3.4	1
107	Serial changes in FIB-4 score and hepatocarcinogenesis in hepatitis B patients treated with or without nucleot(s)ide analogue therapy. <i>GastroHep</i> , 2021 , 3, 37-49	1	1
106	Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. <i>Hepatology Research</i> , 2021 , 51, 201-215	5.1	9
105	Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 538-547	3.4	1
104	Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 269-280	6.2	
103	Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 508-516	3.4	2
102	Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. <i>Gastroenterology Report</i> , 2021 , 9, 133-138	3.3	7
101	Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis. <i>Oncology</i> , 2021 , 99, 518-527	3.6	0
100	Diagnosis of liver fibrosis based on quantification of factors associated with shear wave speed. <i>Choonpa Igaku</i> , 2021 , 48, 193-199	0	
99	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. <i>Liver Cancer</i> , 2021 , 10, 115-125	9.1	5
98	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. <i>Liver International</i> , 2021 , 41, 1389-1397	7.9	14
97	Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison. <i>Targeted Oncology</i> , 2021 , 16, 249-254	5	5

96	Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1293-1303	3.4	0
95	Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. <i>Scientific Reports</i> , 2021 , 11, 14474	4.9	3
94	Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, 1451-1458	2.2	0
93	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. <i>Scientific Reports</i> , 2021 , 11, 16663	4.9	3
92	Lack of hepatitis C virus reinfection in lifetime of Japanese general population with previous hepatitis C virus (HCV) infection successfully treated with anti-HCV therapy. <i>Journal of Infection and Chemotherapy</i> , 2021 , 27, 1674-1675	2.2	0
91	Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1208-1214	11.6	13
90	Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. <i>Liver Cancer</i> , 2020 , 9, 518-528	9.1	7
89	Long-term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model. <i>Hepatology Research</i> , 2020 , 50, 936-946	5.1	3
88	The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. <i>Hepatology International</i> , 2020 , 14, 225-238	8.8	15
87	Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2020 , 98, 295-302	3.6	11
86	Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2020 , 40, 968-976	7.9	25
85	Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	20
84	Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1420-1425	4	1
83	EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. <i>Liver Cancer</i> , 2020 , 9, 734-743	9.1	7
82	Relationship between COVID-19 and liver diseases: the role of hepatologists in clinical practice. <i>Acta Hepatologica Japonica</i> , 2020 , 61, 496-503	0.3	1
81	Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis. <i>Hepatology Research</i> , 2020 , 50, 190-198	5.1	14
80	GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 728-735.e4	6.9	73
79	Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 855-861	4	18

78	Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. <i>Liver Cancer</i> , 2020 , 9, 73-83	9.1	27
77	Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching. <i>Hepatology Research</i> , 2020 , 50, 75-83	5.1	26
76	Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1229-1234	9	9
75	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020 , 73, 1368-1378	13.4	41
74	Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 359-370	6.1	3
73	Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2020 , 10,	3.8	8
72	Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma. <i>Applied Sciences (Switzerland)</i> , 2020 , 10, 7178	2.6	
71	PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication. <i>Journal of Gastroenterology</i> , 2020 , 55, 1162-1170	6.9	2
70	The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC. <i>Scientific Reports</i> , 2020 , 10, 17812	4.9	0
69	Impact of COVID-19 pandemic on surveillance of hepatocellular carcinoma: a study in patients with chronic hepatitis C after sustained virologic response. <i>GastroHep</i> , 2020 , 2, 247	1	6
68	Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imaging-determined proton density fat fraction. <i>Hepatology Research</i> , 2020 , 50, 1319-1327	5.1	5
67	Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. <i>Infectious Diseases and Therapy</i> , 2020 , 9, 851-866	6.2	6
66	Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 2202-2209	4	3
65	Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2019 , 97, 334-340	3.6	26
64	Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz185	1	13
63	Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. <i>Cancer Medicine</i> , 2019 , 8, 3719-3728	4.8	97
62	The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2019 , 54, 829-836	6.9	5
61	Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 2011-2018	4.18	22

60	Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. <i>Liver Cancer</i> , 2019 , 8, 403-411	9.1	17
59	The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1230-1241	6.1	24
58	Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma. <i>Cancers</i> , 2019 , 11,	6.6	2
57	Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. <i>Liver Cancer</i> , 2019 , 8, 121-129	9.1	88
56	Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. <i>Hepatology Research</i> , 2019 , 49, 111-117	5.1	66
55	Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 436-441	4	6
54	Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2019 , 97, 277-285	3.6	44
53	Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model. <i>Journal of Medical Virology</i> , 2019 , 91, 1837-1844	19.7	9
52	Usefulness of Attenuation Imaging with an Ultrasound Scanner for the Evaluation of Hepatic Steatosis. <i>Ultrasound in Medicine and Biology</i> , 2019 , 45, 2679-2687	3.5	54
51	The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1232-1238	6.1	1
50	A case of intraductal papillary neoplasm of the bile duct observed by follow-up ultrasonic examination. <i>Choonpa Igaku</i> , 2019 , 46, 443-452	0	
49	Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 1452-1459	2.2	3
48	Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. <i>Liver Cancer</i> , 2019 , 8, 312-325	9.1	37
47	Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. <i>Cancer Medicine</i> , 2019 , 8, 137-146	4.8	87
46	Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1066-1073	4	27
45	Utility of Attenuation Coefficient Measurement Using an Ultrasound-Guided Attenuation Parameter for Evaluation of Hepatic Steatosis: Comparison With MRI-Determined Proton Density Fat Fraction. <i>American Journal of Roentgenology</i> , 2019 , 212, 332-341	5.4	34
44	Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection. <i>Hepatology Research</i> , 2019 , 49, 512-520	5.1	2
43	Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study. <i>Hepatology Research</i> , 2019 , 49, 125-135	5.1	11

42	The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study. <i>Liver International</i> , 2019 , 39, 448-454	7.9	19
41	Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model. <i>Journal of Gastroenterology</i> , 2018 , 53, 1196-1205	6.9	13
40	Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease. <i>Hepatology Research</i> , 2018 , 48, 549-555	5.1	16
39	A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin-bilirubin grade. <i>Hepatology Research</i> , 2018 , 48, E61-E67	5.1	14
38	Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 918-925	4	20
37	Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 664-670	6.1	15
36	Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1446-1451	3.4	11
35	Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. <i>Journal of Gastroenterology</i> , 2018 , 53, 1276-1284	6.9	20
34	Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. <i>British Journal of Cancer</i> , 2017 , 116, 441-447	8.7	32
33	Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1879-1886	4	9
32	Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. <i>Liver Cancer</i> , 2017 , 6, 204-215	9.1	96
31	Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B. <i>Journal of Hepatology</i> , 2017 , 66, 521-527	13.4	33
30	Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. <i>Digestive Diseases</i> , 2017 , 35, 602-610	3.2	81
29	Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. <i>Liver Cancer</i> , 2017 , 6, 325-336	9.1	102
28	Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 687-694	4	21
27	Post-treatment levels of Fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C. <i>Hepatology Research</i> , 2017 , 47, 1021-1031	5.1	18
26	Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2017 , 1, 899-910	6	25
25	HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. <i>Journal of Hepatology</i> , 2016 , 65, 48-56	13.4	88

24	Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1031-6	4	139
23	Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. <i>Hepatology</i> , 2016 , 64, 1818-1819	11.2	26
22	Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade. <i>Oncology</i> , 2016 , 91, 153-61	3.6	32
21	Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. <i>Liver International</i> , 2016 , 36, 817-26	7.9	47
20	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016 , 114, 744-50	8.7	119
19	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 875-886.e6	6.9	141
18	Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. <i>Journal of Clinical Oncology</i> , 2015 , 33, 550-8	2.2	1097
17	Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. <i>Liver Cancer</i> , 2015 , 4, 126-36	9.1	98
16	High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2014 , 49, 555-63	6.9	46
15	Postinterferon α fetoprotein elevation and risk of hepatocellular carcinoma development after sustained virological response: cause or results?. <i>Hepatology</i> , 2014 , 60, 762-3	11.2	3
14	Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. <i>Journal of Gastroenterology</i> , 2014 , 49, 1485-94	6.9	6
13	Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study. <i>Journal of Medical Virology</i> , 2013 , 85, 65-70	19.7	4
12	Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. <i>Journal of Hepatology</i> , 2013 , 58, 427-33	13.4	108
11	Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. <i>Journal of Hepatology</i> , 2013 , 58, 1174-80	13.4	57
10	Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 357-64	4	10
9	Extended treatment duration overcomes the requirement for profound week-4 interferon responsiveness in order for hepatitis C genotype 1 patients with unfavorable IL-28B genotype to achieve sustained virologic response. <i>Journal of Clinical Virology</i> , 2013 , 57, 381	14.5	
8	High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b. <i>Journal of Gastroenterology</i> , 2011 , 46, 501-9	6.9	10
7	Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. <i>Journal of Gastroenterology</i> , 2011 , 46, 536-44	6.9	38

6	Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. <i>American Journal of Roentgenology</i> , 2011 , 197, 58-63	5.4	130
5	Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. <i>Liver International</i> , 2010 , 30, 527-37	7.9	51
4	Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. <i>Journal of Hepatology</i> , 2009 , 50, 729-35	13.4	38
3	Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 1170-6	6.9	48
2	Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. <i>Liver International</i> , 2005 , 25, 848-53	7.9	53
1	Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. <i>Journal of Hepatology</i> , 1999 , 30, 125-30	13.4	119